X4 Pharmaceuticals

124 articles with X4 Pharmaceuticals

• X4 Pharmaceuticals to Present and Participate in the Canaccord Genuity’s 40th Annual Growth Conference

  8/10/2020

  X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that management will present and conduct one-on-one meetings during the Virtual Canaccord Genuity 40th Annual Growth Conference on Wednesday, August 12th, 2020

• X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 05, 2020

  8/5/2020

  X4 Pharmaceuticals, Inc., a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, announced that, on August 4, 2020, the Compensation Committee of X4’s Board of Directors issued an inducement award to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.

• X4 Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update

  7/30/2020

  Presentation of positive clinical data at EHA 2020 supporting the ongoing Phase 3 trial in WHIM syndrome Initial data expected later this year from Phase 1b clinical trial in Waldenström’s macroglobulinemia Conference call today at 8:30 a.m. ET CAMBRIDGE, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today reporte

• X4 Pharmaceuticals to Announce Second Quarter 2020 Financial Results and Host a Conference Call and Webcast on July 30, 2020

  7/16/2020

  X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that it will report its financial results for the second quarter ended June 30, 2020, and provide an update on recent business highlights, on July 30, 2020. The Company will host a conference call and webcast on the same day at 8:30 a.m. ET to discuss the

• X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 01, 2020

  7/1/2020

  X4 Pharmaceuticals, Inc., a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, announced that, on June 30, 2020, the Compensation Committee of X4’s Board of Directors issued an inducement award to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.

• 

  BioSpace Movers & Shakers, June 12

  6/12/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• X4 Pharmaceuticals Presents Positive Clinical Data from Phase 2 Study of Mavorixafor in WHIM Syndrome at EHA 2020

  6/12/2020

  Sustained efficacy and safety trends observed for up to 28.6 months support ongoing pivotal Phase 3 trial dosing and endpoints, including selection of the measurement of time above threshold for absolute neutrophil count as primary endpoint

• X4 Pharmaceuticals to Host Conference Call and Webcast to Discuss New Phase 2 Clinical Data for Mavorixafor in WHIM Syndrome to be Presented at 25ᵗʰ European Hematology Association Annual Congress

  6/8/2020

  X4 Pharmaceuticals, Inc. announced that it will host a conference call and webcast to discuss new clinical efficacy and safety data from the company’s ongoing Phase 2 open-label extension trial of its lead candidate, mavorixafor, in patients with WHIM syndrome.

• X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jun 01, 2020

  6/1/2020

  X4 Pharmaceuticals, Inc., a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, announced that, on May 29, 2020, the Compensation Committee of X4’s Board of Directors issued an inducement award to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.

• X4 Pharmaceuticals to Present at Two June Virtual Investor Conferences

  5/28/2020

  X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that its management team will present and conduct one-on-one meetings virtually at the Jefferies Global Healthcare Conference 2020 and BMO 2020 Prescriptions for Success Healthcare Conference. Details are as follows: Conference: Jefferies Global Healthcare

• X4 Pharmaceuticals Announces Data from Phase 2 Open-Label Extension Trial of Mavorixafor in WHIM Syndrome as Published in EHA Abstract

  5/14/2020

  Data reveal reductions in annual infections and warts, and sustained dose-dependent increases in neutrophil counts These and additional Phase 2 data to be presented in an e-Poster on June 12 th at the Virtual Edition of the 25 th Congress of the European Hematology Association (EHA)

• X4 Pharmaceuticals Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders

  5/12/2020

  X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) announced today that, due to public health and safety concerns related to the ongoing COVID-19 global pandemic and to support the health and well-being of its stockholders, employees and others, X4 Pharmaceuticals is changing its 2020 Annual Meeting of Stockholders (the “Annual Meeting”) to a virtual-only format that will be held via live audio webcast.

• X4 Pharmaceuticals Provides Corporate Update, Including Expected Impact of COVID-19, and Reports First Quarter 2020 Financial Results

  5/7/2020

  Data from Phase 2 open-label extension trial of mavorixafor in WHIM syndrome to be presented at the Virtual Edition of the 25th European Hematology Association (EHA) Annual Congress in June 2020

• X4 Pharmaceuticals to Announce First Quarter 2020 Financial Results and Provide Recent Business Highlights on May 7, 2020

  4/23/2020

  X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that it will report its financial results and business highlights for the first quarter ended March 31, 2020 at 8:30 a.m. ET on May 7, 2020. The Company will host a conference call and webcast on the same day at 8:30 a.m. ET to

• X4 Pharmaceuticals to Present and Participate in the Virtual 19th Annual Needham Healthcare Conference

  4/9/2020

  April 9, 2020 12:00 UTC X4 Pharmaceuticals to Present and Participate in the Virtual 19 th Annual Needham Healthcare Conference

• X4 Pharmaceuticals Showcases Strategic Focus on WHIM Syndrome During 2020 Analyst Day Webinar

  4/7/2020

  X4 Pharmaceuticals, Inc. today hosted a virtual Analyst Day, A Deep Dive into WHIM Syndrome , the target disease of the company's Phase 3 candidate

• X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 1, 2020

  4/1/2020

  X4 Pharmaceuticals, Inc. announced that on March 31, 2020, the Compensation Committee of X4’s Board of Directors issued an inducement award to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.

• X4 Pharmaceuticals to Host 2020 Analyst Day Webinar:A Deep Dive into WHIM Syndrome

  3/25/2020

  March 25, 2020 12:00 UTC X4 Pharmaceuticals to Host 2020 Analyst Day Webinar: A Deep Dive into WHIM Syndrome - Virtual event to be held on Tuesday, April 7, 2020 at 8:00 a.m. ET - CAMBRIDGE, Mass.--( BUSINESS WIRE )-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that it will host a virtual Analyst Day to discuss its strateg

• X4 Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results

  3/12/2020

  X4 Pharmaceuticals, Inc. today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2019

• X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 2, 2020

  3/2/2020

  X4 Pharmaceuticals, Inc. announced that, on February 28, 2020, the Compensation Committee of X4’s Board of Directors issued an inducement award to a new employee under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.